Combination therapy (GP5, GP9) effectively normalized these parameters, closely approximating those of the uninfected control group (GP1), and highlighting its therapeutic potential in managing both Gram-negative and Gram-positive bacterial infections. The gene discussed is GP5; the disease is gram-positive bacterial infections.